Surotomycin

Drug Profile

Surotomycin

Alternative Names: CB-183,315; CB-315; CDAD therapy - Merck; MK-4261

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cubist Pharmaceuticals
  • Developer Merck & Co
  • Class Antibacterials; Lipopeptides; Peptides
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium infections

Most Recent Events

  • 04 May 2015 Phase-III clinical trials in Clostridium infections in Australia, South Korea and New Zealand (PO)
  • 01 May 2015 Cubist Pharmaceuticals completes a phase III trial in Clostridium-infections in USA, Canada, Israel and European Union (NCT01597505)
  • 04 Feb 2015 Cubist Pharmaceuticals completes enrolment in a phase III trial in Clostridium infections (Clostridium difficile-associated diarrhoea) in USA, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden and United Kingdom (NCT01597505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top